✦ LIBER ✦

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

✍ Scribed by Nancy Egerton

Publisher: Springer
Year: 2010
Tongue: English
Weight: 265 KB
Volume: 66
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1467-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ixabepilone plus capecitabine for Chines

Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment

✍ Jiayu Wang; Ying Fan; Binghe Xu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 267 KB

Efficacy and safety of erlotinib in pati

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

✍ Maura N. Dickler; Melody A. Cobleigh; Kathy D. Miller; Pamela M. Klein; Eric P. 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 181 KB

Therapeutic approaches in young women wi

Therapeutic approaches in young women with advanced or metastatic breast cancer

✍ Andrés García Palomo 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 107 KB

Q-TWiST analysis of ixabepilone in combi

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

✍ Patricia K. Corey-Lisle; Ronald Peck; Pralay Mukhopadhyay; Lucinda Orsini; Shima 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

A phase II study of pemetrexed and carbo

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

✍ August Garin; Alexey Manikhas; Mikhail Biakhov; Mikhail Chezhin; Tatiana Ivanche 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 195 KB

Chemoimmunotherapy with or without oopho

Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer

✍ Hwee-Yong Yap; Gabriel N. Hortobagyi; George R. Blumenschein; Charles K. Tashima 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 533 KB

Ninety-eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy-chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of p